CJC-1295 (No DAC) + Ipamorelin
GHRH analogue + selective GH secretagogue · Research-grade reference material
Identity
- Molecular formula
- N/A — 2-component combination preparation (CJC-1295 No DAC 5mg + Ipamorelin 5mg per vial)
- Molecular weight
- —
- CAS number
- —
Research Background
CJC-1295 (No DAC), also called Modified GRF 1-29, is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH), with substitutions enhancing stability over native GHRH. It binds GHRH receptors on pituitary somatotroph cells, activating adenylate cyclase and cAMP signaling. Without the DAC (Drug Affinity Complex) albumin-binding modification, it has a short plasma half-life, roughly 30 minutes, producing a brief, pulsatile GH release pattern rather than sustained elevation.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts at the ghrelin receptor (GHSR-1a) rather than the GHRH receptor, a mechanistically distinct pathway. It was developed specifically for selectivity: unlike earlier growth hormone-releasing peptides (GHRP-2, GHRP-6), it stimulates GH release without significantly elevating cortisol, prolactin, or ACTH (Raun et al.).
Naming note: foundational CJC-1295 pharmacokinetic data (Teichman et al., Ionescu et al.) was generated using the DAC-conjugated version, not the No-DAC/Mod GRF 1-29 form in this preparation. Research referencing “CJC-1295” without specifying DAC status is often ambiguous between the two, and the two forms have meaningfully different half-lives and dosing implications.
Lab-tested research material
CJC-1295 (No DAC) + Ipamorelin
From $54.00 · HPLC purity 99.91% · Batch AC-CJIP-1 COA
View current batch and sizes →Mechanism
The pairing rationale is receptor complementarity: CJC-1295 (No DAC) stimulates GH release through the GHRH receptor, while Ipamorelin stimulates GH release through a separate receptor (GHSR-1a). Because they act on different receptors upstream of the same GH release pathway, they’re studied together on the premise that combined stimulation produces a larger GH pulse than either compound alone, while the No-DAC form’s short half-life is intended to preserve a natural, pulsatile release pattern rather than sustained elevation.
Findings below derive from preclinical and component-level research and pertain to each compound studied individually. They are not established effects in humans for this blend.
CJC-1295 — GHRH-R binding. Binds the GHRH receptor on anterior pituitary somatotrophs.
CJC-1295 — cAMP signaling. G-protein activation raising cAMP, priming vesicles for GH exocytosis.
CJC-1295 — DPP-IV resistance. Substitutions confer resistance to DPP-IV degradation.
CJC-1295 — DAC extension. DAC formulation binds serum albumin, sustaining stimulation over days.
Ipamorelin — GHS-R1a agonism. Agonist at the ghrelin receptor (GHS-R1a) in hypothalamus and pituitary.
Ipamorelin — calcium signaling. Gq / phospholipase C / IP₃ signaling raising intracellular calcium.
Ipamorelin — granule release. Calcium-mediated granule release triggers the acute GH pulse.
Ipamorelin — receptor selectivity. Selective — minimal cortisol, prolactin or ACTH elevation versus GHRP-2 / GHRP-6 / hexarelin.
Dual-pathway convergence on the somatotroph. GHRH-receptor signaling raises cAMP and primes secretory vesicles; ghrelin-receptor signaling raises intracellular calcium and triggers release. Schematic; not a claim of established human effect for this blend.
State of the Evidence
CJC-1295 (No DAC) and Ipamorelin each have their own individual mechanistic research base. Evidence specifically testing this two-component combination, at this ratio, is more limited than the individual-compound literature for either receptor pathway alone, and much of what circulates as “CJC-1295 research” was conducted using the DAC-conjugated form rather than the No-DAC form in this preparation, worth confirming before treating a given citation as directly applicable.
References: Raun, K., et al. “Ipamorelin, the First Selective Growth Hormone Secretagogue.” European Journal of Endocrinology, vol. 139, no. 5, 1998, pp. 552-561. Jetté, L., et al. “Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates…” Endocrinology, vol. 146, no. 7, 2005, pp. 3052-3058.
The Blend Question — Read This Carefully
This blend differs from most multi-component research preparations in one important respect: there is a published mechanistic rationale for combining these two classes, not merely a marketing one. That rationale should be credited accurately — and its limits stated plainly.
Evidence at a glance
The class-level synergy is real and documented. Research published in 1999 (PMID 10372741) demonstrated that simultaneous stimulation of GHRH and GHS receptor pathways produces a GH response greater than the sum of individual responses — the mechanistic foundation for combining these classes.
Class-level synergy is not product-level evidence. That work concerned GHRH and GHRP compounds generally, not this specific preparation at this supplier’s ratio.
DAC versus non-DAC changes the pharmacology entirely — sustained receptor occupancy versus pulsatile stimulation. Findings do not transfer between the two forms.
Ratios are not standardized across suppliers or lots; results are not directly comparable between vendors.
Attribution is confounded. Without single-compound control arms, an observed effect cannot be assigned to either constituent.
Appropriate characterization: a two-component preparation with a genuine published mechanistic basis for combination at the level of receptor classes, whose specific formulation, ratio and pharmacokinetic form remain uncharacterized in the peer-reviewed literature. Neither constituent is approved for any indication.
Regulatory & status notes
Selected references
- 1. Synergistic GH response to combined GHRH and GHRP receptor stimulation. 1999. PMID 10372741.
- 2. Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab. 2006.
- 3. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
Safety Information
Research-use preparation with limited human data on either component individually, and less on this specific combination and dosing form. Evidence strength varies — see the individual Registry entries for CJC-1295 and Ipamorelin.
No established clinical contraindications. This is an investigational combination with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician. For research and educational purposes only, not for human or veterinary use.
Related Compounds
For research and educational purposes only. Not for human or veterinary use.